Skip to main content
. Author manuscript; available in PMC: 2016 Feb 26.
Published in final edited form as: ACS Nano. 2015 May 6;9(5):5594–5608. doi: 10.1021/acsnano.5b01872

Figure 8.

Figure 8

Treatment of breast (HER2+ and TNBC) and lung cancer BMs. (a) Kaplan–Meier animal survival curve for the treatment of HER2+ BT-474 BM. The nanodrug P/trastuzumab/MsTfR-mAb/HER2-AON improved survival by 57% (median survival 77.5 days for nanodrug vs 49.5 days for PBS control; p < 0.005). (b) P/Hu/MsTfR-mAb/EGFR-AON improved survival of animals with EGFR+ lung cancer BMs by 66% (median survival 48 days for nanodrug vs 29 days for PBS control; p < 0.0008). (c) P/Hu/MsTfR-mAb/EGFR-AON improved survival of animals with EGFR+ TNBC BM by 114% (median survival 62 days for nanodrug vs 29 days for PBS control; p < 0.0006). (d–f) Western analysis of tumors excised from mouse brains. β-Actin and total Akt served as loading controls for HER2/EGFR and pAkt, respectively. N = 3 tumors in each group. Immunostaining also showed dramatic reduction of respective drug targets in nanodrug-treated vs PBS-treated tumors. (g–i) Quantitation of Western blots showed significant reduction of HER2 and pAkt in BT-474 BM upon nanodrug vs PBS treatment (g; *p < 0.05) and of EGFR and pAkt in lung A-549 BM (h; ***p < 0.001 for EGFR and *p < 0.05 for pAkt) and in TNBC BM (i; **p < 0.01 for EGFR and *p < 0.05 for pAkt).